Clinical Trials Browser

Phase 1 × denileukin diftitox × Clear all

NCT00357448 2019-05-14

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01401530 2018-11-23

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Phase 1 Completed

13 enrolled 18 charts

Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, T-Cell, Peripheral

NCT01251952 2017-06-20

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Phase 1 Terminated

2 enrolled 6 charts

Multiple Myeloma

NCT00228358 2014-11-11

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Phase 1 Completed

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00128622 2012-11-12

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00224354 2012-05-21

CLONTAK

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell